By 1991, Dr. Fauci had effectively abandoned testing low-profit repurposed drugs in the parallel track CRI program. But he used a parallel track to open a loophole in the FDA drug approval system, a loophole large enough to drive through truckloads of Pharma’s new high-profit patented antivirals.
